1. Home
  2. SLGL vs AVXL Comparison

SLGL vs AVXL Comparison

Compare SLGL & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

N/A

Current Price

$75.40

Market Cap

247.1M

Sector

Health Care

ML Signal

N/A

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$2.60

Market Cap

276.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLGL
AVXL
Founded
1997
2004
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.1M
276.2M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
SLGL
AVXL
Price
$75.40
$2.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$110.00
$22.00
AVG Volume (30 Days)
25.0K
1.1M
Earning Date
05-22-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$223.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.80
$2.61
52 Week High
$97.97
$13.99

Technical Indicators

Market Signals
Indicator
SLGL
AVXL
Relative Strength Index (RSI) 57.90 37.44
Support Level $66.48 N/A
Resistance Level $81.64 $3.50
Average True Range (ATR) 6.76 0.18
MACD 0.83 0.00
Stochastic Oscillator 88.07 1.04

Price Performance

Historical Comparison
SLGL
AVXL

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: